CSBio CSBio

X
[{"orgOrder":0,"company":"Stevanato Group","sponsor":"Bexson Biomedical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Stevanato Group And Bexson Biomedical Announce Collaboration To Develop A Customized Wearable Ketamine Delivery Device","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"ITALY","productType":"Small molecule","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Stevanato Group"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            The collaboration will focus on developing a customized version of the SG EZ-be Pod®, a wearable drug delivery device, for Bexson’s proprietary ketamine formulation, BB106.

            Lead Product(s): Ketamine Hydrochloride

            Therapeutic Area: Neurology Product Name: BB106

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Bexson Biomedical

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration September 21, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY